Kalmar Investments Inc. DE Sells 67,126 Shares of Luminex Corp. (LMNX)
Kalmar Investments Inc. DE cut its position in shares of Luminex Corp. (NASDAQ:LMNX) by 6.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 946,975 shares of the company’s stock after selling 67,126 shares during the period. Kalmar Investments Inc. DE owned approximately 2.23% of Luminex Corp. worth $19,157,000 at the end of the most recent quarter.
A number of other large investors also recently bought and sold shares of LMNX. Aperio Group LLC raised its stake in Luminex Corp. by 36.6% in the first quarter. Aperio Group LLC now owns 13,048 shares of the company’s stock worth $253,000 after buying an additional 3,499 shares during the last quarter. Prudential Financial Inc. raised its position in shares of Luminex Corp. by 5.3% in the first quarter. Prudential Financial Inc. now owns 93,840 shares of the company’s stock worth $1,820,000 after buying an additional 4,700 shares in the last quarter. BlackRock Group LTD raised its position in shares of Luminex Corp. by 4.6% in the first quarter. BlackRock Group LTD now owns 64,271 shares of the company’s stock worth $1,247,000 after buying an additional 2,828 shares in the last quarter. BlackRock Fund Advisors raised its position in shares of Luminex Corp. by 1.6% in the first quarter. BlackRock Fund Advisors now owns 3,017,364 shares of the company’s stock worth $58,537,000 after buying an additional 46,200 shares in the last quarter. Finally, BlackRock Institutional Trust Company N.A. raised its position in shares of Luminex Corp. by 1.6% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,083,514 shares of the company’s stock worth $21,020,000 after buying an additional 17,102 shares in the last quarter. 79.83% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Luminex Corp. (NASDAQ:LMNX) traded down 1.77% on Wednesday, hitting $21.70. The company had a trading volume of 151,044 shares. The company has a market cap of $944.99 million, a price-to-earnings ratio of 22.65 and a beta of 0.42. The company has a 50 day moving average of $22.11 and a 200-day moving average of $21.05. Luminex Corp. has a 12-month low of $17.29 and a 12-month high of $23.75.
Luminex Corp. (NASDAQ:LMNX) last posted its quarterly earnings data on Thursday, July 28th. The company reported $0.33 EPS for the quarter, beating the Zacks’ consensus estimate of $0.15 by $0.18. Luminex Corp. had a net margin of 16.60% and a return on equity of 13.65%. The business had revenue of $64.20 million for the quarter, compared to analyst estimates of $61.20 million. During the same quarter last year, the business earned $0.27 earnings per share. The business’s revenue for the quarter was up 8.9% on a year-over-year basis. On average, analysts forecast that Luminex Corp. will post $0.63 earnings per share for the current year.
A number of research analysts have weighed in on the company. Avondale Partners assumed coverage on Luminex Corp. in a research note on Wednesday, October 12th. They set an “outperform” rating and a $27.00 price target on the stock. Jefferies Group increased their price target on Luminex Corp. from $21.00 to $23.00 and gave the stock a “hold” rating in a research note on Thursday, July 28th. Zacks Investment Research raised Luminex Corp. from a “hold” rating to a “buy” rating and set a $24.00 price target on the stock in a research note on Tuesday, July 26th. Finally, JPMorgan Chase & Co. raised Luminex Corp. from an “underweight” rating to a “neutral” rating and increased their price target for the stock from $18.00 to $22.00 in a research note on Thursday, August 18th. Six research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Luminex Corp. presently has a consensus rating of “Hold” and a consensus price target of $23.00.
Luminex Corp. Company Profile
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company has a range of instruments using its xMAP technology, including its LUMINEX 100/200 systems offer 100-plex testing; the Company’s FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry.
Receive News & Stock Ratings for Luminex Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex Corp. and related stocks with our FREE daily email newsletter.